Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PerkinElmer firms up India base:

This article was originally published in Clinica

Executive Summary

PerkinElmer has acquired the outstanding minority interest in the sales and marketing business, PerkinElmer India, from Labindia Instruments.100% ownership of PerkinElmer India will provide the Waltham, Massachusetts group with a platform to deliver its extensive portfolio of medical devices to the Indian market. The transaction also sees Jai Shankar appointed as president of PerkinElmer India, a role that will allow him to oversee the company's expansion of its product portfolio, and set its strategic direction in the region. The company also announced it plans to open a new India headquarters in Mumbai, as well as a new technical support and applications center in the second half of 2007. PerkinElmer India currently employs approximately 170 people in nine sites throughout the country, including Bangalore and Mumbai.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT048955

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel